HK1201843A1 - Anti-polyubiquitin antibodies and methods of use - Google Patents

Anti-polyubiquitin antibodies and methods of use

Info

Publication number
HK1201843A1
HK1201843A1 HK15101412.1A HK15101412A HK1201843A1 HK 1201843 A1 HK1201843 A1 HK 1201843A1 HK 15101412 A HK15101412 A HK 15101412A HK 1201843 A1 HK1201843 A1 HK 1201843A1
Authority
HK
Hong Kong
Prior art keywords
methods
polyubiquitin antibodies
polyubiquitin
antibodies
Prior art date
Application number
HK15101412.1A
Other languages
English (en)
Chinese (zh)
Inventor
Robert F Kelley
Marissa L Matsumoto
Vishva Dixit
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1201843A1 publication Critical patent/HK1201843A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15101412.1A 2011-08-05 2015-02-09 Anti-polyubiquitin antibodies and methods of use HK1201843A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515729P 2011-08-05 2011-08-05
PCT/US2012/049771 WO2013022848A1 (en) 2011-08-05 2012-08-06 Anti-polyubiquitin antibodies and methods of use

Publications (1)

Publication Number Publication Date
HK1201843A1 true HK1201843A1 (en) 2015-09-11

Family

ID=47668865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101412.1A HK1201843A1 (en) 2011-08-05 2015-02-09 Anti-polyubiquitin antibodies and methods of use

Country Status (10)

Country Link
US (4) US9321844B2 (xx)
EP (1) EP2739651B1 (xx)
JP (2) JP6411212B2 (xx)
KR (1) KR20140054177A (xx)
CN (1) CN104011078B (xx)
BR (1) BR112014002716A2 (xx)
HK (1) HK1201843A1 (xx)
MX (1) MX2014001238A (xx)
RU (1) RU2630637C2 (xx)
WO (1) WO2013022848A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AR057237A1 (es) 2005-12-15 2007-11-21 Genentech Inc Metodos y composiciones para actuar sobre la poliubiquitina
WO2009126350A2 (en) 2008-01-18 2009-10-15 Genentech, Inc. Methods and compositions for targeting polyubiquitin
WO2011130499A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
MX2014001238A (es) 2011-08-05 2014-09-22 Genentech Inc Anticuerpos contra poliubiquitina y métodos de uso.
JP6568514B2 (ja) * 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
BR112017026169A2 (pt) 2015-06-29 2018-08-14 Oreal composição na forma de emulsão de óleo em água e método de prevenção e/ou controle da oleosidade da pele
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3475298A1 (en) * 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
CA3053275A1 (en) * 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding psma, nkg2d and cd16
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CN117447610B (zh) * 2023-10-27 2024-04-26 重庆天科雅生物科技有限公司 一种嵌合抗原受体（car）及其在制备抗肿瘤药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07238096A (ja) 1994-02-25 1995-09-12 S R L:Kk 抗ポリユビキチン・モノクローナル抗体およびポリユビキチンの測定方法
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20070218079A1 (en) 2004-05-12 2007-09-20 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method to induce rnai in prokaryotic organisms
KR101413048B1 (ko) 2005-08-25 2014-06-30 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 발암의 줄기세포 융합 모델
AR057237A1 (es) 2005-12-15 2007-11-21 Genentech Inc Metodos y composiciones para actuar sobre la poliubiquitina
EP1808493A3 (en) 2006-01-13 2007-11-21 Hybrigenics S.A. Substrates and methods for assaying deubiquitinating enzymes activity
WO2008121813A2 (en) 2007-03-30 2008-10-09 Genentech, Inc. Modulation of cytokine production
WO2009126350A2 (en) 2008-01-18 2009-10-15 Genentech, Inc. Methods and compositions for targeting polyubiquitin
WO2011130499A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
MX2014001238A (es) 2011-08-05 2014-09-22 Genentech Inc Anticuerpos contra poliubiquitina y métodos de uso.

Also Published As

Publication number Publication date
JP2014531894A (ja) 2014-12-04
US20230348581A1 (en) 2023-11-02
US20210017260A1 (en) 2021-01-21
US9321844B2 (en) 2016-04-26
CN104011078B (zh) 2016-11-09
EP2739651B1 (en) 2019-02-20
JP2017200484A (ja) 2017-11-09
US20160304591A1 (en) 2016-10-20
US20130058955A1 (en) 2013-03-07
EP2739651A1 (en) 2014-06-11
WO2013022848A1 (en) 2013-02-14
US11597761B2 (en) 2023-03-07
BR112014002716A2 (pt) 2017-06-13
EP2739651A4 (en) 2015-02-25
MX2014001238A (es) 2014-09-22
CN104011078A (zh) 2014-08-27
KR20140054177A (ko) 2014-05-08
US10738106B2 (en) 2020-08-11
RU2630637C2 (ru) 2017-09-11
JP6411212B2 (ja) 2018-10-24
RU2014108309A (ru) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1255608A1 (zh) 抗htra1抗體及使用方法
HK1212256A1 (en) Anti-mcam antibodies and associated methods of use -mcam
HK1205517A1 (en) Anti sez6 antibodies and methods of use sez6
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
HK1209432A1 (en) Anti-jagged antibodies and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
HK1201537A1 (en) Anti-kdr antibodies and methods of use -kdr
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2670245A4 (en) ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
EP2670436A4 (en) FOXC1 ANTIBODIES AND METHOD FOR THEIR USE
HK1184173A1 (en) Anti-kdr antibodies and methods of use -kdr